Compare Impinj Inc (PI) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Impinj Inc vs Recursion Pharmaceuticals Inc — how do they compare? Impinj Inc trades at $188.02 (market cap $5.60B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.31B). The key difference: Impinj Inc is far larger — about 2.4× Recursion Pharmaceuticals Inc's market cap, and Impinj Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Impinj Inc for 22 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| PI | RXRX | |
|---|---|---|
Market Cap | $5.60B | $2.31B |
Volume | 9,929 | 40,478,768 |
Sector | Technology | Health |
52-Week High | $241.91 | $6.79 |
52-Week Low | $91.34 | $2.84 |
Typical Hold Time | 22 Days | 22 Days |
Enterprise Value | $5.73B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Impinj (PI) trades at $191.04, up 3.81% today, showing strong momentum with a bullish technical signal from moving averages. The stock has beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.86 exceeding expectations. However, the company remains unprofitable with a net income margin of -7.26% for 2026. Analyst consensus is strongly positive with 16 buy ratings and a $178.83 price target, though the current price exceeds this target. Recent news highlights the CFO's stock sale and participation in industry conferences.
The outlook for PI is mixed; strong revenue growth and bullish analyst sentiment support upside, but profitability challenges and high valuation ratios pose risks. Investment opportunity lies in the company's positioning in RFID technology, while key risks include sustained losses and competitive pressures. The stock's proximity to resistance at $192 suggests near-term volatility.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
